House committee blocks psychedelic amendments to a defense bill. Texan doctors want to investigate psychedelic psychotherapy’s effectiveness for late-stage cancer distress. Researchers have compared the brain activity of depressive patients on psilocybin vs. antidepressants.
Berkeley joins the list of cities that have decriminalized entheogens. California is one step away from legalizing natural psychedelics. Two philanthropists have made significant contributions toward psychedelic research.
Australia becomes a pioneer in psychedelic legalization. New study finds a link between microdosing and authenticity. The struggle to expand access to psychedelics continues in the U.S. Congress.
In the world of psychedelic news, exciting developments are unfolding in the advancement of psychedelic research and policy.
Some of the biggest psychedelic news this week include the Colorado Senate passing a bill to regulate psychedelics.
Psychedelic news this week include multiple states passing or putting forward legislation tackling psychedelic research.
This week witnessed a wave of US states dwelling on psychedelic policies to be included in voting agendas, while cutting-edge DMT research is being subsidized for mental health studies.
This week, the psychedelic news-sphere has been abuzz with a few standout stories. From important policy updates to psychedelic IPOs, it’s clear that the field of psychedelics continues to grow and evolve at an exciting rate—so we’ve rounded up the top seven headlines here for your convenience.
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed’s stock is removed from an index; and more!
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.